Prospective Activity of PLG0206, an Engineered Antimicrobial Peptide, on Chronic Periprosthetic Joint Infection Total Knee Arthroplasty Components Ex Vivo: The Knee Explant Analysis (KnEA) Study.
Microbiol Spectr
; 9(3): e0187921, 2021 12 22.
Article
in En
| MEDLINE
| ID: mdl-34817227
ABSTRACT
PLG0206 is an engineered antimicrobial peptide that has completed phase 1 clinical studies. A prospective study was completed on explanted implants from chronic periprosthetic joint infections (n = 17). At a concentration of 1 mg/mL for 15 min, there was a mean 4-log10 reduction (range, 1 to 7) in the bacterial CFU identified from the implants. IMPORTANCE Chronically infected prosthetics of the knee were exposed to PLG0206, an engineered antimicrobial peptide, at a concentration of 1 mg/mL for 15 min. A mean 4-log10 reduction (range, 1 to 7) in the number of bacteria occurred, which may translate to improved clinical outcomes for persons with prosthetic joint infection of the knee.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Postoperative Complications
/
Bacteria
/
Prosthesis-Related Infections
/
Arthroplasty, Replacement, Knee
/
Antimicrobial Peptides
Type of study:
Observational_studies
Limits:
Humans
Language:
En
Journal:
Microbiol Spectr
Year:
2021
Document type:
Article